Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was completed on the same day. Both companies are based in the United States and operate within the healthcare sector. The deal value was not disclosed in the available reports. The consideration for the acquisition consists of shares. This structure indicates a stock-based exchange rather than a cash payment. The acquisition is classified as a strategic move within the industry. No specific financial figures or additional terms were reported alongside the announcement. The process concluded swiftly, with the completion date matching the announcement date. This suggests a straightforward execution of the agreed terms. The parties involved are Alaunos Therapeutics, Inc. as the buyer and Velaris Therapeutics, Inc. as the target. The sector label confirms the healthcare context for this corporate action. The status of the deal is recorded as completed. There are no pending regulatory hurdles or future milestones noted in the data. The transaction represents a definitive step in the consolidation of these two entities. The lack of disclosed value prevents any assessment of the financial scale. The share-based consideration aligns with common practices in this sector. The rapid timeline from announcement to completion highlights the efficiency of the process. The deal is now fully executed and closed.